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Abstract Cancer cells have accelerated metabolism and
high glucose requirements. The up-regulation of specific
glucose transporters may represent a key mechanism by
which malignant cells may achieve increased glucose up-
take to support the high rate of glycolysis. In present study
we analyzed the mRNA and protein expression of GLUT1
and GLUT3 glucose transporters by quantitative real-time
polymerase chain reaction (Q-PCR) and Western blotting
technique in 76 cases of endometrial carcinoma and 70
cases of breast carcinoma. SLC2A1 and SLCA2A3 mRNAs
expression was found, respectively in 100% and 97.4%
samples of endometrial cancers and only in 50% and 40%
samples of breast cancers. In endometrial cancers GLUT1
and GLUT3 protein expression was identified in 67.1% and
30.3% of cases. Analogously, in breast cancers in 48.7% and
21% of samples, respectively. The results showed that both
endometrial and breast poorly differentiated tumors (grade 2
and 3) had significantly higher GLUT1 and GLUT3 expres-
sion than well-differentiated tumors (grade 1). Statistically
significant association was found between SLCA2A3 mRNA
expression and estrogen and progesterone receptors status in
breast cancers. GLUT1 has been reported to be involved in
the uptake of glucose by endometrial and breast carcinoma
cells earlier and the present study determined that GLUT3
expression is also involved. GLUT1 and GLUT3 seem to be
important markers in endometrial and breast tumors
differentiation.
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Introduction
Glucose uptake and glycolytic metabolism are enhanced in
cancer cells compared to normal cells [1, 2]. This observa-
tion was first reported by Otto Warburg several decades ago
[3, 4]. He hypothesized that conversion of glucose into
lactate combined with suppression of mitochondrial func-
tion reflect the major metabolic change in malignant trans-
formation [3, 4].
Transport of glucose across the plasma membrane is the
first rate-limiting step for glucose metabolism and is medi-
ated by facilitative glucose transporter proteins (GLUTs) [5,
6]. Fourteen members of the glucose transporter family have
been identified. The genes belong to the solute carrier 2A
family with gene symbol SLC2A. The glucose transporters
differ in their tissue distribution and each transporter protein
possesses different affinities for glucose and other hexoses
such as fructose [5, 6]. GLUT1 is broadly expressed in the
body tissues and is involved in glucose uptake in the basic
state [6]. Elevated level of GLUT1 have been shown in
almost all human cancers including brain, breast, head and
neck, bladder, renal, colorectal, lung and ovarian cancers
[6]. Some studies have demonstrated that the level of
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istics. Comparatively higher levels of expression are seen in
cancers of higher grade and proliferative index and in can-
cers of lower degree of differentiation. GLUT1 expression
has been associated with increased malignant potential,
invasiveness and poor prognosis in lung, colorectal, gastric
and ovarian cancers [7–11].
GLUT3 is also expressed in human malignant tissue, but
not so frequently as GLUT1. GLUT3 isoform seems to be a
predominant glucose transporter in highly malignant glial
cells of human brain [12]. Oligonucleotide microarray anal-
ysis revealed that SLC2A3 (gene encoded GLUT3) over-
expression was correlated with tumor size, pathologic stage
and recurrence in oral tongue carcinoma [13]. GLUT3
protein expression evaluated by immunohistochemistry
is indicator of poor prognosis outcome in non-small lung
carcinoma, oral squamous cell carcinoma and laryngeal
carcinoma [7, 14, 15]. However, GLUT3 mRNA or pro-
tein expressions are not correlated with any clinicopath-
ological parameters in case of thyroid and ovarian
cancers [16–18].
In present study we analyzed the mRNA and protein
expression levels of GLUT1 and GLUT3 in endometrial
and breast cancers and the relationship between their ex-
pression and clinicopathological parameters.
Materials and Methods
Patients and Samples
The studied materials were obtained from Department of
Gynecological Oncology Copernicus Memorial Hospital,
Łódź, Poland and from Department of Clinical Pathomor-
phology Polish Mother’s Memorial Hospital, Research In-
stitute, Łódź, Poland.
The materials comprised samples of 76 endometrial car-
cinomas and 70 breast ductal carcinomas. Information re-
garding the clinical and pathological characteristics of the
patient populations was obtained from the medical records.
The endometrial and breast cancer patients characteristics
are present in Tables 1 and 2, respectively. Endometrial
normal tissue samples were obtained from 27 patients who
had undergone hysterectomy. In the case of normal breast
tissue, the material used for the study came from 36 women
after a total mastectomy. All the clinical material were
excised by a surgical pathologist.
Endometrial carcinomas were classified according to the
criteria of the International Federation of Gynecology and
Obstetrics(FIGO). Histologicaltypingand grading weredone
according to the WHO classification [19]. All breast carcino-
mas were classified according the Bloom and Richardson
grading system and according TNM staging system.
Table 1 Characteristics of patients and endometrial cancer samples
Characteristic Number of patients
(n076)
Median age (range) 62.5 (31 – 85)
FIGO stage
I3 5
II 31
III 9
IV 1
Histological grade
G1 14
G2 49
G3 13
Depth of myometrial invasion
<1/2 41
>1/2 35
Hyperplasia
No 62
Yes 14
Myomas
No 60
Yes 16
Lymph node metastasis
No 60
Yes 16
Table 2 Characteristics of patients and breast cancer samples
Characteristic Number of patients (n070)
Median age (range) 57.3 (39–72)
Tumor grade according to Bloom-Richardson system
I2 1
II 30
III 19
Tumor size
T1 22
T2 33
T3-T4 15
Lymph node metastasis
No 44
Yes 26
Menopausal status
Premenopausal 23
Postmenopausal 47
ER and PR status
ER+PR+ 33
ER-PR+/ER+PR- 16
ER-PR- 21
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The tissue specimens collected in the operation room were
prepared and evaluated by an experienced pathologist.
Samples were stored at -80°C until RNA preparation.
Total RNA was isolated using Trizol
® Reagent (Sigma
Aldrich, USA) according to manufacturer’s protocol and
quantified spectrophotometrically. First-strand cDNAs
were obtained by reverse transcription of 1 μg of total
RNA using RevertAid
TM First strand cDNA synthesis kit
(Fermentas International, Lithuania) following the manu-
facturer’s protocol.
Quantitative Real-Time RT-PCR
Real-time gene expression analysis of target genes
(SLC2A1 and SLC2A3) was performed using TaqMan
®
Gene Expression Assays (Applied Biosystems, USA)
according to manufacturer’s instructions. The GAPDH
gene was used as internal control. The assay numbers
for these genes were as follows: Hs00892681_m1,
Hs00359840_m1, Hs99999905_m1.
Each PCR reaction was performed in a 10 μl volume that
included 5 μl of 2x TaqMan Universal PCR MasterMix
(Applied Biosystems, USA), 4.5 μl of water diluted cDNA
template (50 ng) and 0.5 μl of TaqMan
® Gene Expression
Assay consisted of a pair of unlabeled PCR primers and
TaqMan probe with a FAM
TM. The RT-qPCR reaction was
carried out using the Mastercycler ep realplex (Eppendorf)
under the following conditions: denaturation for 10 min at
95°C followed by 50 cycles of 15 s at 95°C, 1 min annealing
and extension at 60°C.
Relative RNA quantification was performed using the
ΔCt method. ΔCt (Ctgene—CtGAPDH) values were recal-
culated into relative copy number values (number of
SLC2A1 and SLC2A3 mRNA copies per 1000 copies of
GAPDH mRNA).
SLC2A1 and SLC2A3 Gene Copy Number Quantification
To determine the SLC2A1 and SLC2A3 genes amplification,
copy number quantification was carried out using quantita-
tive real-time PCR Mastercycler ep realplex (Eppendorf)
with the glucokinase (GCK) gene used as the reference
gene. The real-time PCR primers are listed in Table 3.
Real-time PCR was performed in 50 μl reaction volumes
that contained 2x Power SYBR Green PCR Master Mix
(Applied Biosystems, USA) and 0.9 mM forward and re-
verse primers. PCRs conditions were: 5 s at 95°C followed
by 40 cycles consisting of 15 s at 95°C and 30 s at 60°C.
ΔCt was calculated by a Ct value of GCK taking away that
of SLC2A1 and SLC2A3 and three or more ΔCt was defined
as amplified.
Western Blotting Analysis
The samples (50 μg protein/lane) of homogenates were
resolved by 8% SDS-PAGE and electroblotted onto
Immobilon-P transfer membranes (Millipore, Bedford,
Massachusetts, USA). The blots were incubated 1 h with
rabbit polyclonal anti-GLUT1 (Abcam, UK) or mouse
monoclonal anti-GLUT3 antibodies (Santa Cruz Biotech-
nology. Inc., USA) in a 1:1000 and 1:400 dilution, respec-
tively. After being washed three times with TBST (Tris
buffered saline with Tween-20), the membranes were incu-
bated 1 h with goat anti-rabbit or anti-mouse antibodies
conjugated with horseradish peroxidase (1:5000 dilution).
The membranes were again washed three times with TBST
and incubated with peroxidase substrate solution (3,3’-
diaminobenzidine -DAB). Gel-Pro
® Analyzer software
(Media Cybernetics Inc., USA) was used for densitometry
analysis of protein bands. The integrated optical density
(IOD) of the bands, in a digitized picture, was measured.
Evaluation of ER and PR
ER and PR status was determined by immunohistochemical
method as part of the routine clinical practice. Using the
immunohistochemical assay, tumors were classified as pos-
itive if more than 10% of the cells showed nuclear staining
for the receptor. This information was received together with
the characteristics of clinical material.
Statistical Analysis
The statistical analyses were performed using the
STATISTICA version 9.0 (StatSoft, Poland). Since lev-
els of expression in endometrial and breast cancer speci-
mens did not show normal distribution (Kolmogorov-
Smirnov test) the non-parametrical statistical tests were
applied (Mann–Whitney U test, Spearman rank analy-
sis). Kruskal-Wallis test with post-hoc multiple compar-
isons were used according to clinical data. P values
come from post-hoc tests. A p-value<0.05 was consid-
ered as statistically significant.
Table 3 Primers used for SLC2A1 and SLCA2A3 gene copy number
quantification
Gene Primer Sequence
SLC2A1 Forward TGTGCAACCCATGAGCTAA
Reverse CCTGGTCTCATCTGGATTCT
SLC2A3 Forward TTCGTCTCTAGCCTGCACTG
Reverse ACACAACTTCTCCGGGTGAC
GCK Forward CGGATGCAGAAGGAGATGGA
Reverse CATCTTCACACTGGCCTCTTCA
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Endometrial Carcinoma
GLUT1 mRNA expression was found in all 76 samples of
endometrial cancers and positive GLUT3 mRNA expression
was demonstrated in 97,4% of the cases (74/76). In the case
of normal tissue, GLUT1 and GLUT3 mRNA expression
was observed in 22.2% (6/27) and 48.1% (13/27) samples,
respectively. Mean GLUT1 and GLUT3 gene expressions in
normal and cancerous tissue are presented in Table 4. The
table contains p-values for comparison of normal and neo-
plastic tissues. The relative GLUT3 mRNA level was much
lower compared to GLUT1 mRNA level.
Amplification of the SLC2A1 gene was found in 4% (3/76)
of endometrial cancer cases, but in none of normal tissue. In the
case of SLC2A3 gene, amplification was not observed in any
cancerous and normal samples. The results are summarized in
Table 5.
Of the carcinoma samples, 67.1% (51/76) showed
GLUT1 protein expression. GLUT3 protein expression
was observed in 30.3% (23/76). In case of normal tissue
GLUT1 protein was detected in 26% (7/27) and GLUT3 in
14.8% (4/27) studied samples. Mean GLUT1 and GLUT3
protein expressions in normal and cancerous tissues are
present in Table 4.
A representative results of analyses of GLUT1 and
GLUT3 protein expression in homogenates of endometrial
and breast carcinomas are shown in Fig. 1.
A significant correlation between the GLUT1 and GLUT3
expression levels determined by real-time PCR and those
obtained by Western blotting was noted (Spearman’s rank
analysis, p<0.01,p<0.05, respectively).
There were no significant differences (p>0.05) in
GLUT1 and GLUT3 mRNA/protein expression, between
tumors in different stage of development according to FIGO
classification. However, the GLUT1 mRNA and protein
expression was significantly higher in tumors of grade 2
than in tumors of grade 1 (p<0.05). GLUT3 mRNA and
protein expression increased significantly with increasing tu-
mor grade (p<0.05). There was no correlation between the
other demographic and clinicopathological parameters (age,
depth of myometrial invasion, hyperplasia, myomas, lymph
node metastasis) and GLUT1 or GLUT3 expression. Due to
the similar relationship between the GLUT1 and GLUT3
mRNAs and proteins expression levels and clinicopathologi-
cal parameters, wehave shown on the graphsonlydatafor the
mRNA (Fig. 2.). The values shown on the graphs apply only
tocases with positive gene expression. We have alsoanalyzed
the relationship between GLUT1 and GLUT3 mRNA/protein
expression, but we did not find any correlations.
Breast Carcinoma
Positive GLUT1 and GLUT3 mRNAs expression was found
respectively in 50% (35/70) and 40% (28/70) of breast cancer
cases. In normal breast tissue, GLUT1 and GLUT3 mRNA
expression was observed in 41.7% (15/36) and 13.9% (5/36)
samples, respectively. Mean SLC2A1 and SLC2A3 gene
expressions in normal and cancerous tissues are present in
Table 4. Similarly as in the case of endometrial cancer, the
relative GLUT3 mRNA level was lower compared to GLUT1
mRNA level.
Table 4 Mean SLC2A1 and
SLC2A3 gene and GLUT1 and
GLUT3 protein expression in
normal and cancerous tissues.
The table contains p-values for
comparison of expression in
normal and neoplastic tissue
Gene [copies of gene mRNA per 1000
copies of GAPDH mRNA]
Protein [Integrated Optical Density]
SLC2A1 SLCA2A3 GLUT1 GLUT3
Endometrium
Normal 213.4±87.6 46.2±24.8 124.3±65.9 53.1±25.4
Cancer 356.6±143.7 71.3±23.1 185.3±43.2 71.5±35.7
p>0.05 p<0.05 p<0.05 p>0.05
Breast
Normal 86.2±21.5 58.6±18.6 94.2±36.7 40.7±22.7
Cancer 273.7±145.2 73.3±30.2 137.9±32.8 50.5±31.5
p<0.05 p>0.05 p>0.05 p>0.05
Table 5 SLC2A1 and SLC2A3 gene amplifications in endometrial and
breast cancers
Tissue type SLC2A1 copy
number
SLC2A3 copy
number
Three or more
copies
Three or more
copies
Endometrial cancer 3/76 0/76
Endometrial normal tissue 0/27 0/27
Breast cancer 7/70 2/70
Normal breast tissue 0/36 1/36
724 A. Krzeslak et al.The study of gene copy number showed that the SLC2A1
gene amplification was found in 8.6% (6/70) of cancer
cases, but in none normal tissue sample. In the case of
SLC2A3 gene, amplification was observed in 2.8% (2/70)
of cancerous samples and in one normal tissue. The results
are summarized in Table 5.
Of the carcinoma samples, 48.7% (37/76) showed
GLUT1 protein expression. GLUT3 protein expression
was observed in 22.8% (16/70). In case of normal tissue
GLUT1 protein was detected in 22.2% (8/36) and GLUT3
in 16.7% (6/36) of studied samples. Mean GLUT1 and
GLUT3 protein expressions in normal and cancerous tissue
are present in Table 4. Figure 1 shows representative results
of immunoblotting of GLUT1 and GLUT3 protein in breast
normal and cancerous samples.
A significant correlation between the GLUT1 and
GLUT3 mRNA and protein expression levels was observed
(Spearman’s rank analysis, p<0.05 in both cases).
There were no statistically significant differences in
GLUT1 mRNA/protein expression between tumors with
different demographic and clinicopathological parameters
(age, tumor grade, tumoral size, lymph node metastasis,
menopausal status, ER and PR status). However, the
results showed a trend of poorly differentiated tumors
(grade 2 and 3) to be more frequently GLUT1 positive
(53,3% and 52,6%, respectively) than well differentiated
one (grade 1; 38,1%). There were statistically significant
differences in GLUT3 mRNA expression levels between
grade 3 tumors and grade 1 tumors (p<0.05). In the case
of protein expression level such dependence was not
showed. Statistically significant association was found
between GLUT3 mRNA expression and estrogen and
progesterone receptors status (Fig. 3.). For the other
demographic and clinicopathological parameters correla-
tion with GLUT3 mRNA/protein expression was not
showed. Analogously as in endometrial studies, due to
the similar relationship between the GLUT1 and GLUT3
genes and proteins expression levels and clinicopatholog-
ical parameters, we have shown on the graphs only data
for the mRNA. There was no relationship between
GLUT1 and GLUT3 mRNA/protein expression in breast
normal and cancerous samples.
Discussion
Tumor cells must have increased access to glucose to
support the high rate of glycolysis and satisfy their great
need of energy. The up-regulation of specific glucose trans-
porters may represent a key mechanism by which malig-
nant cells may achieve increased glucose uptake and
compensate the lack of energy caused by inefficient anaer-
obic glycolysis. There is little information in the literature
regarding glucose transporters expression in endometrial
cancers. However, the GLUT1 and GLUT8 have been
reported to be involved in the uptake of glucose by endo-
metrial carcinoma cells [20]. The results of previous im-
munohistochemical studies showed that GLUT1 was
overexpressed in endometrial cancers compared to benign
endometrial epithelium [21]. Upregulation of GLUT1
expression with increasing grade of tumors was demon-
strated [20]. The results of our studies also showed higher
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Fig. 1 A representative results of GLUT1 a and GLUT3 b protein
expression analyses in homogenates of endometrial and breast carci-
nomas. Lower panels show the results of quantitative densitometric
analysis. a and b lane 1- normal endometrium, lane 2—endometrial
carcinoma, lane 3—normal breast tissue, lanes 4–6—breast cancer
samples classified according the Bloom and Richardson grading
system as I, II, III, respectively
GLUT1, GLUT3 in Endometrial and Breast Cancers 725expression of GLUT1 mRNA in less differentiated carci-
nomas (grade 2 and 3) compared to well-differentiated ones
(grade 1).
To the best of our knowledge this study is the first
documenting GLUT3 mRNA and protein expression in
endometrial cancers. GLUT3 gene amplification also has
not been studied so far. Relative GLUT3 mRNA expression
level in endometrial carcinoma was lower than GLUT1.
However, the expression of GLUT3 significantly increased
with the histological grade of tumors. The expression of
GLUT3 in grade 3 tumors was about 10 and 4 times higher
than in grade 1 and grade 2, respectively. Our results
showed no relationship between the expression of GLUT1
and GLUT3 in endometrial cancers and the number of gene
copies. These results suggest that both GLUT1 and GLUT3
are involved in glucose uptake in endometrial carcinoma
and they may be an important markers in tumor differenti-
ation. There was no relationship between GLUT1 or
GLUT3 mRNA expression and demographic or clinocopa-
thological parameters such as tumor stage, coexistence of
myomas and hyperplasia, lymph node metastasis. Therefore,
the significance of their expression on prognosis in endo-
metrial carcinomas requires further clarification employing
a larger cohort.
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Fig. 2 Expression of SLC2A1
and SLCA2A3 mRNA
measured by real-time PCR in
endometrial cancers via
clinicopathological parameters.
Bars indicate mean±SEM
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breast cancers have given variable results. Some immuno-
histochemical studies detected GLUT1 expression in about
50% and the other only in 25% of breast tumors [22–24].
Younes et al. [22] demonstrated expression of GLUT1 in
42% of 118 breast tumors, with increased expression in
cancers of higher grade and proliferative activity. The results
of our study showed GLUT1 mRNA and protein expression
in about 50% of breast cancers. There were no statistically
significant differences in GLUT1 expression between
tumors of different grade and stage. However, the results
showed a trend of poorly differentiated tumors to be more
frequently GLUT1 positive than well differentiated ones
(grade 1 about 38% grade 2 and 3 about 50%). These results
are similar to results of Ravazoula et al. [25] who studied 78
infiltrating ductal carcinoma sa n ds h o w e de x p r e s s i o no f
GLUT1 in 28% of grade 1, 63.8 of grade 2 and 58.7 of
grade 3 carcinomas.
Younes et al. [26] did not demonstrate GLUT3 expres-
sion in breast cancer and Godoy et al. [27] showed that
GLUT3 was weakly expressed only in 3 of 33 cases of
invasive ductal carcinoma and was absent in 12 normal
tissues. The results of our study showed that GLUT3 mRNA
expression was present in 40% of breast cancer cases. How-
ever, similarly to endometrial cancers the relative GLUT3
mRNA level was much lower than in case of GLUT1.
Higher GLUT3 expression was significantly associated with
poor histological grade of breast cancers. Kang et al. [23]
showed that expression of GLUT1 correlated significantly
with estrogen and progesterone receptors status. Our results
did not show such a correlation in case of GLUT1 expres-
sion, but there was significantly higher expression of
GLUT3 in estrogen and progesterone receptor positive can-
cers than in receptor negative carcinomas. These results are
consistent with hypothesis of hormonal regulation of glu-
cose transporters expression in cancers. Rivenzon-Segal et
al. [28] found that estrogen-induced changes in glycolysis in
orthotopic MCF7 human breast cancer xenografts appear to
be mediated by regulation of GLUT1 expression. Increased
GLUT12 protein levels after estrogen treatment in MCF-7
cells had also been demonstrated [6]. It is possible that
estrogen or progesterone may influence GLUT3 expression
in breast cancer as well. Amplification of the studied by us
genes was found in a small number of cases and therefore
we conclude that it did not affect the expression levels.
In conclusion, the expression of GLUT1 has been reported
to be involved in the uptake of glucose by endometrial and
breast carcinoma cells and the present study determined that
GLUT3 expression is also involved. GLUT1 and GLUT3
may be important markers in endometrial and breast tumors
differentiation. Clarification of the role in glucose metabolism
of GLUT specific isoforms could potentially improve tumors
detection and treatment.
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Fig. 3 Expression of SLC2A1 and SLCA2A3 mRNA measured by
real-time PCR in breast cancers via clinicopathological parameters.
Bars indicate mean±SEM
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